S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
|ClinicalTrials.gov Identifier: NCT00068601|
Recruitment Status : Completed
First Posted : September 11, 2003
Results First Posted : April 4, 2017
Last Update Posted : April 4, 2017
RATIONALE: Goserelin blocks hormone production in the ovaries. It is not yet known whether ovarian suppression using goserelin will prevent ovarian failure (early menopause) in women receiving chemotherapy for breast cancer.
PURPOSE: This randomized phase III trial is studying how well giving goserelin together with chemotherapy works compared with chemotherapy alone in preventing early menopause in women with stage I, stage II, or stage IIIA breast cancer.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Infertility Menopausal Symptoms||Drug: cyclophosphamide Drug: goserelin acetate||Phase 3|
- Compare the rate of premature ovarian failure in women with stage I-IIIA hormone receptor-negative breast cancer treated with chemotherapy with vs without goserelin.
- Compare the rate of ovarian dysfunction in patients treated with these regimens.
- Compare ovarian reserve in patients treated with these regimens.
- Describe the pregnancy rates in patients treated with these regimens.
OUTLINE: This is a randomized study. Patients are stratified according to age (under 40 vs 40 to 49) and planned chemotherapy regimen (3- to 4-month/course anthracycline-based vs 6- to 8-month/course anthracycline-based vs 3- to 4-month/course non-anthracycline-based vs 6- to 8-month/course non-anthracycline-based). Patients are randomized to 1 of 2 treatment arms.
- Arm 1: Patients receive cyclophosphamide-containing chemotherapy alone. Patients are followed at 1, 2, and 5 years.
- Arm 2: Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 416 patients (208 per treatment arm) will be accrued for this study within 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||257 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer|
|Study Start Date :||October 2003|
|Primary Completion Date :||January 2014|
|Study Completion Date :||September 2016|
Active Comparator: Standard Chemotherapy
Patients receive cyclophosphamide-containing chemotherapy alone.
Part of planned chemotherapy regimen
Experimental: Chemotherapy Plus Goserelin
Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
Part of planned chemotherapy regimenDrug: goserelin acetate
- Rate of Premature Ovarian Failure at 2 Years [ Time Frame: 2 years ]Ovarian failure at two years is defined as amenorrhea (absence of menstrual bleeding) for the preceding six months AND the presence of follicle-stimulating hormone (FSH) in the post-menopausal range.
- Rate of Ovarian Dysfunction at 2 Years [ Time Frame: 2 years ]Ovarian dysfunction is defined as amenorrhea for the preceding three months and the presence of FSH, estradiol and/or inhibin B levels in the postmenopausal range.
- Rate of Ovarian Dysfunction at 1 Year [ Time Frame: 1 year ]Ovarian dysfunction is defined as amenorrhea for the preceding three months and the presence of FSH, estradiol and/or inhibin B levels in the postmenopausal range.
- Ovarian Reserve at 1 and 2 Years [ Time Frame: 1 and 2 years ]Measurements of ovarian reserve will consist of "Day 2 - 4" levels of FSH, estradiol and inhibin B during Month 12/13 and Month 24/25 (or if amenorrheic, anytime during Month 12/13 and Month 24/25).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00068601
Hide Study Locations
|Australia, New South Wales|
|Mater Hospital - North Sydney|
|North Sydney, New South Wales, Australia, 2060|
|Royal North Shore Hospital|
|St. Leonards, New South Wales, Australia, 2065|
|Newcastle Mater Misericordiae Hospital|
|Waratah, New South Wales, Australia, 2298|
|Australia, South Australia|
|Royal Adelaide Hospital Cancer Centre|
|Adelaide, South Australia, Australia, 5000|
|Flinders Medical Centre|
|Bedford Park, South Australia, Australia, 5042|
|Royal Hobart Hospital|
|Hobart, Tasmania, Australia, 7000|
|Ballarat Oncology and Haematology Services|
|Ballarat, Victoria, Australia, 3350|
|Box Hill Hospital|
|Box Hill, Victoria, Australia, 3128|
|Monash Medical Center - Clayton Campus|
|Clayton, Victoria, Australia, 3168|
|Peter MacCallum Cancer Centre|
|East Melbourne, Victoria, Australia, 3002|
|East Ringwood, Victoria, Australia, 3135|
|St. Vincent's Hospital - Melbourne|
|Fitzroy, Victoria, Australia, 3065|
|Royal Melbourne Hospital|
|Parkville, Victoria, Australia, 3050|
|Australia, Western Australia|
|Royal Perth Hospital|
|Perth, Western Australia, Australia, 6000|
|Centre Hospitalier Hutois|
|Huy, Belgium, 4500|
|Leuven, Belgium, B-3000|
|Centre Hospitalier Regional de la Citadelle|
|Liege, Belgium, 4000|
|CHU Liege - Domaine Universitaire du Sart Tilman|
|Liege, Belgium, B-4000|
|Oostende, Belgium, 8400|
|Centre Hospitalier Peltzer-La Tourelle|
|Verviers, Belgium, B-4800|
|National Institute of Oncology|
|Budapest, Hungary, 1122|
|Ospedali Riuniti di Bergamo|
|Bergamo, Italy, 24100|
|Ospedale degli Infermi - ASL 12|
|Biella, Italy, 13900|
|Ospedale Civile Ramazzini|
|Carpi, Italy, 41012|
|Ospedale Alessandro Manzoni|
|Lecco, Italy, 23900|
|European Institute of Oncology|
|Milano, Italy, 20141|
|Auckland City Hospital|
|Auckland, New Zealand, 1|
|Oncology Institute of Southern Switzerland|
|Bellinzona, Switzerland, CH-6500|
|Bern, Switzerland, CH-3010|
|Centre Hospitalier Universitaire Vaudois|
|Lausanne, Switzerland, 1011|
|Oncology Institute of Southern Switzerland - Locarno|
|Locarno, Switzerland, CH-6601|
|Oncology Institute of Southern Switzerland - Lugano|
|Lugano, Switzerland, CH-6900|
|Oncology Institute of Southern Switzerland - Mendrisio|
|Mendrisio, Switzerland, CH-6850|
|Thun, Switzerland, 3600|
|Principal Investigator:||Halle C Moore, MD||The Cleveland Clinic|
|Study Chair:||Kathy S. Albain, MD||Loyola University|
|Study Chair:||Silvana Martino, DO||John Wayne Cancer Institute|
|Study Chair:||Ann H. Partridge, MD, MPH||Dana-Farber Cancer Institute|
|Study Chair:||Lori J. Goldstein, MD||Fox Chase Cancer Center|
|Study Chair:||Kelly-Anne Phillips||Peter MacCallum Cancer Centre, Australia|